

Prediction of adenomyosis diagnosis based on MRI

Citation for published version (APA):

Rees, C., van de Wiel, M., Nederend, J., Huppelschoten, A. G., Mischi, M., van Vliet, H. A. A. M., & Schoot, B. C. (2023). Prediction of adenomyosis diagnosis based on MRI. *Journal of Endometriosis and Uterine Disorders*, 2, Article 100028. <https://doi.org/10.1016/j.jeud.2023.100028>

Document license:

CC BY-NC-ND

DOI:

[10.1016/j.jeud.2023.100028](https://doi.org/10.1016/j.jeud.2023.100028)

Document status and date:

Published: 01/06/2023

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.



Original article

Prediction of adenomyosis diagnosis based on MRI

C.O. Rees^{a,b,c,*}, M. van de Wiel^a, J. Nederend^d, A. Huppelschoten^a, M. Mischi^b,
H.A.A.M. van Vliet^{a,c}, B.C. Schoot^{a,b,c}

^a Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, Netherlands

^b Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands

^c Department of Reproductive Medicine, Ghent University Hospital, Ghent, Belgium

^d Department of Radiology, Catharina Hospital, Eindhoven, Netherlands



ARTICLE INFO

Keywords:
Adenomyosis
MRI
Hysterectomy
Pathology
Diagnosis

ABSTRACT

Objective: Development of a multivariate prediction model based on MRI and clinical parameters for histological adenomyosis diagnosis.

Materials and methods: This single centre retrospective cohort study took place in the gynaecological department of a referral hospital. In all, 296 women undergoing hysterectomy with preoperative pelvic MRI between 2007–2022 were included. MRI scans were retrospectively assessed for adenomyosis markers (junctional zone [JZ] parameters, high signal intensity [HSI] foci in a blinded fashion. A multivariate regression model for histopathological adenomyosis diagnosis was developed based on MRI and clinical variables from univariate analysis with $p < 0.1$ and factors deemed clinically relevant.

Results: 131/296 women (44.3%) had histopathological adenomyosis. Patients had comparable age at hysterectomy, BMI and clinical symptoms, $p > 0.05$. Adenomyosis patients more often had: undergone a curettage (22.1% vs. 8.9%, $p = 0.002$), a higher mean JZ thickness (9.40 vs. 8.35 mm, $p < .001$), maximal JZ thickness (16.00 vs. 13.40 mm, $p < .001$), mean JZ/myometrium ratio (0.56 vs. 0.49, $p = .040$), and JZ differential (8.60 vs. 8.15 mm, $p = .003$). Presence of HSI foci was the strongest predictor for adenomyosis (39.7% vs. 8.9%, $p < .001$). Based on the parameters age and BMI, history of curettage, dysmenorrhoea, abnormal uterine bleeding (AUB), mean JZ, JZ differential ≥ 5 mm, JZ/myometrium ratio > 40 , and presence of HSI foci, a predictive model was created with a good area under the curve (AUC) of .776.

Conclusions: This is the first study to create a diagnostic tool based on MRI and clinical parameters for adenomyosis diagnosis. After sufficient external validation, this model could function as a useful clinical decision-making tool in women with suspected adenomyosis.

1. Introduction

The gold standard for diagnosing adenomyosis is histopathological after hysterectomy. Adenomyosis can also be diagnosed using magnetic resonance imaging (MRI) [1–3]. Accurate diagnosis on MRI remains challenging as a consensus on diagnostic criteria is lacking [4]. Clinically, adenomyosis can be suspected based on symptoms (dysmenorrhoea, abnormal uterine bleeding [AUB] and infertility [4,5]), but this can be difficult due to up to a third of patients being asymptomatic [4,6]. Ultrasound (TVUS) diagnostic criteria do exist and are the most commonly used non-invasive diagnostic tool [7–9], but are dependent on experienced sonographers [10–12]. Furthermore, TVUS is less reliable in cases of mild or atypical adenomyosis [7,13]. Moreover, in cases with

combined pathology (e.g. adenomyosis and fibroids, or adenomyosis and endometriosis), TVUS diagnosis can be extra challenging [7]. In cases such as these, MRI can help lead to a more definitive diagnosis.

In the frequently associated condition endometriosis [14], reported diagnostic delay is up to nine years [15,16]. The diagnostic delay for adenomyosis is unknown. The mental and physical toll on women suffering from either of these conditions is considerable [17]. Especially in women of fertile age, there is a need for an accurate diagnostic tool so that appropriate management can be implemented swiftly. Early diagnosis is clinically relevant even in mild cases, due to a potential for reproductive sequelae [5]. Such a tool could also be used to predict certain clinical outcomes such as treatment response, or fertility outcomes.

Abbreviations: MRI, magnetic resonance imaging; TVUS, transvaginal ultrasound; JZ, junctional zone; BMI, body mass index; OR, odds ratio; AUB, abnormal uterine bleeding.

* Corresponding author. Afdeling Gynaecologie & Verloskunde, Michelangelolaan 2, 5623EJ Eindhoven, Netherlands.

E-mail address: connie.rees@catharinaziekenhuis.nl (C.O. Rees).

<https://doi.org/10.1016/j.jeud.2023.100028>

Received 23 May 2023; Accepted 30 May 2023

Available online 1 June 2023

2949-8384/© 2023 Published by Elsevier Masson SAS on behalf of Society of Endometriosis and Uterine Disorders (SEUD). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

There are a wide range of MRI parameters that can be used to characterise adenomyosis, such as junctional zone (JZ) thickness, myometrial signal intensity and uterine size [3,18]. Many of them have not been investigated for diagnostic accuracy, and little is likewise known about their correlation with clinical outcomes [3,19]. Despite attempts to create (imaging-based) classification systems for adenomyosis [20,21], there exists no clinically applicable tool for prediction of adenomyosis diagnosis on MRI.

This study aims to create a multivariate prediction model for histopathological diagnosis of adenomyosis based on a combination of MRI parameters and clinical criteria prior to hysterectomy.

2. Materials and methods

2.1. Study objective

To develop a multivariate prediction model for adenomyosis diagnosis on histopathology after hysterectomy based on MRI and clinical parameters.

2.2. Setting

Gynaecological department of a Dutch regional referral teaching hospital.

2.3. Design

Single centre retrospective observational cohort study

2.4. Patient selection and eligibility

Patients were selected through screening of electronic hospital patient records in Healthcare Information eXchange (HiX) (ChipSoft BV, Amsterdam, the Netherlands), based on electronic search queries in CTcue (CTcue BV, Amsterdam, the Netherlands). Relevant search terms are presented in [supplementary file A](#).

Women were eligible for inclusion if they underwent a hysterectomy due to benign pathology in our centre between 2007 and March 2022 and had preoperative pelvic MRI available. Subjects were included regardless of symptoms. Subjects were excluded if: they did not have a pelvic MRI prior to hysterectomy, they had an unsuitable MRI protocol (see [appendix B](#) for further specification), they were post-menopausal (due to no longer active disease), had a gynaecological malignancy, or if no pathology report was available after hysterectomy. Patients were also excluded if they explicitly stated that they did not want their information to be used for research purposes.

2.5. Outcomes

The primary outcome assessed in this study is the histopathological diagnosis of adenomyosis after hysterectomy. Secondary outcomes include clinical and MRI parameters of included patients.

2.6. Histopathology diagnosis

Adenomyosis was diagnosed based on histopathology if endometrial glands were seen in the myometrium:

- at least one low power field from (an irregular) endo-myometrial junction, or;
- 1 to 2.5 mm below basal layer of endometrium, or;
- deeper than 25% of the overall myometrial thickness.

2.7. Local MRI protocol

All pelvic MRIs were carried out with either a 1.5T or 3T MRI system (Philips, Ingenia, the Netherlands). Local protocol included a

T2-weighted turbo spin echo (T2-TSE) sequence in the sagittal, axial, and coronal planes, and a T1-weighted turbo spin echo (T1-TSE) sequence in the axial plane. A slice thickness of 3 millimetres was generally used, with variations ranging from 3–5 millimetres. All patients were pre-treated with an antispasmodic agent (1 mL of 20 mg/mL Buscopan[®], Sanofi, Paris, France) intravenously or intramuscularly to minimise the effects of uterine and bowel peristalsis on image interpretation. Some patients received multiple pelvic MRIs prior to hysterectomy. In those cases, the MRI closest to the hysterectomy was chosen for the assessment. See [supplementary file B](#) for full details.

2.8. MRI assessment

Two investigators (MvdW and CR) independently reviewed all pelvic MRIs for signs of adenomyosis blinded to the final histopathological diagnosis. Adenomyosis was suspected when one or more of the following features was present: (irregular) JZ > 12 mm, presence of myometrial high signal intensity (HSI) foci and/or asymmetric enlarged uterus (other than due to presence of leiomyoma's). Measurements were done using Spectra IDS7 version 21.1 (Linköping, Sweden). [Table S1](#) shows an overview and definition of the parameters that were measured. Consensus was reached if there was a difference of < 2 mm. If discrepancies existed between the assessments of the two investigators, expertise was sought from a pelvic radiologist (J.N.). The researchers independently concluded whether an MRI adenomyosis diagnosis was suspected, after which the pathology report was consulted to review the conclusive histopathological diagnosis. The influence of uterine contractions on JZ measurements was minimised by confirming (maximal) JZ thickness in more than one imaging plane. In the case of bad quality MRIs, or extremely abnormal uteri affecting the ability for assessment, only those MRI parameters that could be reliably measured were assessed.

2.9. Data management

To store patient data, protected software, Research Manager (Research Manager, Deventer, the Netherlands), was used. Data pertaining to patients were given a pseudonymized study ID and could therefore not be traced back to the individual patient.

2.10. Data analysis and model development

The study was conducted conform both the STROBE [22] and the TRIPOD statements [23] (see [supplementary files C and D](#) for the appropriate checklists). All statistical analyses were conducted with IBM SPSS Statistics, version 28.0 (IBM Corp., Armonk, NY, USA). Flowcharts were created using Miro (Miro, Amsterdam, the Netherlands). Except for univariate logistic regression analysis, a *P*-value of < .05 was considered statistically significant for all variables.

Between group differences were compared between patients with and without a histopathological adenomyosis diagnosis after hysterectomy. For clinical characteristics and primary MRI parameters, counts and frequencies were reported. For normally distributed continuous variables, means and standard deviations were calculated. For continuous variables that were not normally distributed, medians and inter-quartile ranges were given. To assess between group differences for continuous variables, Student's *t*-test and Mann-Whitney U test were used. For categorical variables, the Chi Squared test was used.

For all possible predictive factors, sensitivity, specificity, PPV, NPV, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and accuracy were calculated. Potential threshold values of continuous variables were investigated using receiver operator characteristics (ROC) curves and area under the curve (AUC) to identify appropriate cut-off values, and to test the prognostic diagnostic potential for histopathological adenomyosis diagnosis.

For the development of the prediction model, the methodology as described by Grant et al. [24] and the TRIPOD guidelines were followed

[23] For all individual potential predictors for a histopathological adenomyosis diagnosis, a univariate logistic regression analysis was first performed. The odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) were reported. Missing values were dealt with by multiple imputations. Furthermore, interaction terms were used to test possible interaction between individual predictive factors. Tests for multicollinearity were performed as well to assess potential correlation between predictors. Individual variables were used for inclusion into the multivariate logistic regression model if they had a P -value < 10 in the univariate logistic regression analysis, or if they were considered clinically relevant, and if they had a high diagnostic performance (sensitivity/specificity $> 70\%$ or AUC > 0.70). Overfitting of the model was avoided by reducing the number of variables included in the model and by using shrinkage factors. Model fit was further improved by including additional predictive power of continuous variables based on locally weighted smoothing (LOESS).

The final model was evaluated for discrimination and calibration performance. The AUC was obtained to discriminate between women with and without a histopathological adenomyosis diagnosis after hysterectomy. To assess the calibration of the predicted probabilities, and to show the relation between predicted and observed probabilities for the histopathological adenomyosis diagnosis, an observed to expected ratio was calculated and a Hosmer and Lemeshow test was performed.

2.11. Ethics statement

This study was approved by the local medical ethical review board, with study number nWMO-2020.135. Informed consent was waived due to the retrospective study design.

3. Results

3.1. Patient selection

In all, 296 women out of 1139 potentially eligible women were included for analysis. See Fig. 1 for detailed overview of the patient selection and exclusion procedure.

3.2. Patient characteristics

Table 1 presents patient characteristics of patients with and without a histopathological adenomyosis diagnosis. Out of 296 patients undergoing hysterectomy, 131 (44.2%) received adenomyosis diagnosis based on histopathology. In all, 34.4% (45/131) patients had concomitant uterine fibroids, and 53.4% (70/131) had concomitant endometriosis (as diagnosed by MRI or laparoscopy). In general, age, body mass index (BMI), medical history, and clinical symptoms were comparable between patients with and without adenomyosis ($p > .05$). However, patients with a histopathological diagnosis of adenomyosis more often had a history of curettage after miscarriage (22.1% vs. 8.9%, $p = .002$).

3.3. MRI characteristics

Table 2 presents primary MRI characteristics of patients with and without a histopathological diagnosis of adenomyosis. In all, 21 patients were not assessed on MRI due to a poor quality of the MRI, or the inability of the researchers to identify the endometrium or the JZ (e.g., due to disruption of the normal uterine anatomy in patients with severe uterine




Fig. 1. Flowchart of patient selection and exclusion.

Table 1
Patient characteristics.

	Histopathology		P-value
	Adenomyosis (n = 131)	No adenomyosis (n = 165)	
Demographics			
Age at MRI	42.24 ± 5943	40.94 ± 6019	.617
BMI	26.82 ± 5539	26.38 ± 5474	.416
Intoxications			
Smoking	35 (26.7%)	44 (28.0%)	.629
Medical history			
History of curettage ^a	29 (22.1%)	14 (8.9%)	.002
Gravidity	3.0 ± 2.0	2.5 ± 2.0	.342
Parity	2.0 ± 2.0	2.0 ± 1.0	.814
History of caesarean section	33 (25.2%)	55 (35.0%)	.542
Irregular cycle ^b	30 (22.9%)	36 (22.9%)	.562
Hormonal medication ^c	57 (43.5%)	62 (39.5%)	.426
Endometriosis ^d	70 (53.4%)	72 (45.9%)	.200
Uterine fibroids	45 (34.4%)	65 (41.4%)	.220
Symptoms			
Dysmenorrhoea	96 (73.3%)	99 (63.1%)	.491
AUB	81 (61.8%)	88 (56.1%)	.201
Chronic pain	95 (72.5%)	110 (70.1%)	.779
Subfertility	26 (19.8%)	39 (24.8%)	.417
Dyschezia	18 (13.7%)	30 (19.1%)	.185
Dyspareunia	50 (38.2%)	66 (42.0%)	.903

MRI: magnetic resonance imaging; BMI: body mass index; AUB: abnormal uterine bleeding.

^a In the context of miscarriage or termination of pregnancy.

^b Defined as < 21 days or > 35 days in duration or cycle length that varied from month to month by > 4 days.

^c Combined oral contraceptive pill (COC), progesterone only pill (POP), GnRH antagonist, levonorgestrel intra-uterine device (Ln-IUD).

^d As diagnosed on MRI or laparoscopy.

Table 2
MRI characteristics for patients with adenomyosis diagnosis versus those without.

	Histopathology		P-value
	Adenomyosis (n = 131)	No adenomyosis (n = 165)	
MRI features			
Mean JZ (mm)	9.40 ± 6.40	8.35 ± 4.60	< .001
JZ Max (mm)	16.0 ± 10.10	13.40 ± 6.20	< .001
JZ Diff (mm)	8.60 ± 7.20	8.15 ± 5.50	.003
Mean JZ/MYO	0.56 ± 0.29	0.49 ± 0.21	.040
Mean JZ asymmetry (mm)	0.10 ± 3.50	0.35 ± 2.90	.518
Mean wall thickness (mm)	18.72 ± 6.50	17.12 ± 6.00	.069
Mean wall asymmetry (mm)	1.73 ± 6.50	1.02 ± 6.10	.295
Mean uterine length (mm)	88.80 ± 17.90	89.05 ± 18.70	.899
Mean uterine volume (mm ³)	240,774.63 ± 167,707.00	214,199.41 ± 160,215.50	.613
Adenomyosis focus SI	402.00 ± 191.00	422.50 ± 213.80	.363
SI ratio	2.18 ± 1.02	2.38 ± 1.15	.521
JZ Max ≥ 12 mm (n)	87 (66.4%)	73 (46.5%)	.004
JZ Diff ≥ 5 mm (n)	109 (83.2%)	99 (63.1%)	.024
JZ/MYO > 4 (n)	92 (70.2%)	98 (62.4%)	.021
HSI foci (n)	52 (39.7%)	14 (8.9%)	< .001

MRI: magnetic resonance imaging; JZ: junctional zone; Max: maximum; JZ Diff: junctional zone differential; JZ/MYO: junctional zone to myometrium ratio; SI: signal intensity; HSI: high signal intensity.

fibroids). Furthermore, 52 MRIs were re-assessed and discussed with a third investigator due to discrepancies between the two researchers. Most discrepancies related to the presence of high signal intensity (HSI) foci (n = 31) and individual JZ measurements (including JZ Max) (n = 15) (see Table S2 for further details).

Significant differences between groups were found for mean JZ thickness, maximal JZ thickness, and JZ differential (JZ Diff) (p < .001, < .001, and .003, respectively). Similar differences were observed for the cut-offs of JZ ≥ 12 mm, JZ Diff ≥ 5 mm, and JZ to myometrium ratio (JZ/MYO) > 4 (p = .004, .024, and .021, respectively). Compared to patients without adenomyosis, the MRIs of patients with adenomyosis more often showed HSI foci (39.7% vs. 8.9%, p < .001). Fig. 2 shows illustrative

examples of these MRI features in patients with and without a histopathological diagnosis of adenomyosis.

3.4. Diagnostic accuracy

Table 3 presents the diagnostic accuracy of MRI in general and the individual potential predictors of adenomyosis. MRI overall had a sensitivity of 50.4%, a specificity of 66.9%, a PPV of 55.9%, a NPV of 61.8%, a positive LR of 1.5, and a negative LR of 0.7. The overall accuracy was 59.4%. A history of curettage showed an overall accuracy of 59.7%, with a sensitivity of 22.1%, a specificity of 91.1%, a PPV of 67.4%, a NPV 58.4%, a positive LR 2.5, and a NLR of 0.9. Additionally, AUB had a




Fig. 2. Illustrative examples of MRI's of two included patients. A. MRI measurements in a patient without histopathological diagnosis of adenomyosis. Mean JZ thickness was 8.7 mm (< 12 mm), JZ Max was 9.8 mm (< 12 mm), and JZ Diff was 3.8 mm (< 5 mm). JZ/MYO was .50 (> .40), and HSI foci were not present. B. MRI measurements in a patient with histopathological diagnosis of adenomyosis. Mean JZ thickness was 24.6 mm (≥ 12 mm), JZ Max was 45.8 mm (≥ 12 mm), and JZ Diff was 40.5 mm (≥ 5 mm). JZ/MYO was 0.74 (> .40), and HSI foci were present (white arrows).

Table 3
Diagnostic accuracy of MRI and clinical parameters for histopathological adenomyosis diagnosis.

	Histopathological adenomyosis diagnosis						Overall accuracy
	Sensitivity	Specificity	PPV	NPV	PLR	NLR	
MRI overall	50.4%	66.9%	55.9%	61.8%	1.5	0.7	59.4%
Intoxications							
Smoking	38.9%	57.7%	44.3%	52.2%	0.9	1.1	49.0%
Medical history							
History of curettage	22.1%	91.1%	67.4%	58.4%	2.5	0.9	59.7%
History of caesarean section	91.7%	5.2%	37.5%	50.0%	0.9	1.6	70.2%
Irregular cycle	36.1%	59.6%	45.5%	50.0%	0.9	1.1	48.3%
Hormonal medication	53.3%	51.9%	47.9%	57.3%	1.1	0.9	52.5%
Symptoms							
Dysmenorrhoea	94.1%	8.3%	49.2%	60.0%	1.0	0.7	50.0%
AUB	94.2%	11.1%	47.9%	68.8%	1.1	0.5	49.7%
Chronic pain	97.9%	2.7%	46.3%	60.0%	1.0	0.8	46.7%
Subfertility	19.8%	75.2%	40.0%	5.9%	0.8	1.1	50.0%
Dyschezia	23.4%	67.4%	37.5%	51.2%	0.7	1.1	47.3%
Dyspareunia	72.5%	26.7%	43.1%	55.8%	1.0	1.0	46.5%
Endometriosis	53.4%	54.1%	49.3%	50.7%	1.2	0.9	53.8%
Uterine fibroids	34.4%	58.6%	40.9%	51.7%	0.8	1.1	47.6%
MRI features							
Mean JZ Max ≥ 12 mm	71.9%	45.5%	54.4%	64.2%	1.3	0.6	58.0%
Mean JZ Diff ≥ 5 mm	88.6%	22.0%	52.4%	66.7%	1.1	0.5	54.8%
Mean JZ/MYO ≥ 4	71.3%	29.5%	48.4%	52.6%	1.0	1.0	49.6%
HSI foci	40.3%	91.0%	78.8%	64.8%	4.8	0.7	68.1%

PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio; AUB: abnormal uterine bleeding; JZ Max: maximal junctional zone thickness; JZ Diff: junctional zone differential; JZ/MYO: junctional zone to myometrium ratio; HSI: high signal intensity.

sensitivity of 94.2%, a specificity of 11.1%, a PPV of 47.9%, and a NPV of 68.8%. The positive LR of AUB was 1.1, negative LR 0.5, and overall accuracy 49.7%. A JZ Diff ≥ 5 mm on MRI had an overall accuracy of 54.8%, with a sensitivity of 88.6%, a specificity of 22.0%, a PPV of 52.5%, a NPV of 66.7%, a positive LR of 1.1, and a negative LR of 0.5. The sensitivity of the presence of HSI foci was 40.3%, the specificity was 91.0%, the PPV was 48.4%, and the NPV was 52.6%. The positive LR was 4.8, the negative LR was 0.7, and the overall accuracy was 68.1%. Reader (CR and MvdW) detection versus initial radiologist diagnosis is shown in [Table S3](#).

In tests for individual prognostic diagnostic potential using the ROC-curve, no continuous variables showed an AUC ≥ 0.7. Highest AUCs were found for mean JZ thickness and JZ Max (AUC .624) (data not shown).

3.5. Prediction of histopathological adenomyosis

[Table 4](#) presents the results of both univariate and multivariate logistic regression analysis. Univariate logistic regression analysis showed *P*-values < .10 for: age at MRI, history of curettage, mean JZ thickness, JZ Max, JZ Diff, JZ/MYO, mean uterine volume, JZ Max ≥ 12 mm, JZ Diff ≥ 5 mm, and the presence of HSI foci. The potential predictors showed no two-way interaction; however, mean JZ thickness, JZ Max, and JZ Diff did show multicollinearity. These variables were not included in the multivariate regression model to avoid overoptimism. Nevertheless, high diagnostic performance was found for dysmenorrhoea and AUB (sensitivity/specificity > 70%). Additionally, due to clinical relevance, BMI was manually forced into the multivariate model. The

Table 4
Univariate and multivariate logistic regression analysis for histopathological adenomyosis diagnosis.

Variable	Univariate analysis			Multivariate analysis		
	dOR	95% CI	P-value	dOR	95% CI	P-value
Age at MRI	1037	.997–1079	.070	1044	.966–1128	.275
BMI	1015	.972–1059	.506	1036	.965–1112	.327
Intoxications						
Smoking	.868	.488–1543	.629			
Medical history						
History of curettage	2904	1462–5770	.002	2332	.734–7414	.151
Gravidity	1074	.849–1359	.551			
Parity	1038	.821–1313	.753			
History of Caesarean section	.600	.114–3148	.546			
Irregular cycle	.833	.450–1543	.562			
Hormonal medication	1232	.737–2058	.426			
Endometriosis	1355	.851–2157	.201			
Uterine fibroids	.741	.458–1197	.221			
Symptoms						
Dysmenorrhoea	1455	.499–4243	.493	1103	.210–5787	.907
AUB	2025	.674–6080	.208	1038	.260–4139	.958
Chronic pain	1295	.212–7917	.779			
Subfertility	.749	.427–1314	.314			
Dyschezia	.631	.318–1250	.187			
Dyspareunia	.957	.473–1937	.903			
MRI features						
Mean JZ	1132	1061–1207	< .001	1203	1040–1392	.013
JZ Max	1083	1039–1128	< .001			
JZ Diff	1089	1035–1146	< .001			
Mean JZ asymmetry	1031	.979–1087	.250			
Mean wall thickness	.997	.972–1023	.823			
Mean wall asymmetry	1004	.988–1021	.613			
Mean JZ/MYO	4148	1102–15.61	.035			
Mean uterine length	.995	.987–1002	.173			
Mean uterine volume	1000	1000–1000	.043			
Adenomyosis focus SI	1001	1000–1002	.162			
SI ratio	.936	.774–1131	.492			
JZ Max ≥ 12 mm	2138	1268–3605	.004			
JZ Diff ≥ 5 mm	2202	1097–4420	.026	1535	.441–5351	.501
JZ/MYO > 4	1040	.614–1763	.883	0.194	.060–621	.006
HSI foci	6850	3568–13,148	< .001	4650	1857–11,648	.001

dOR: diagnostic odds ratio; CI: confidence interval; BMI: body mass index; AUB: abnormal uterine bleeding; JZ: junctional zone; JZ Max: maximal junctional zone thickness; JZ Diff: junctional zone differential; JZ/MYO: junctional zone to myometrium ratio; SI: signal intensity; HSI: high signal intensity.

final model included age at MRI, BMI, history of curettage, dysmenorrhoea, AUB, mean JZ thickness, JZ Diff ≥ 5 mm, JZ/MYO > .40, and the presence of HSI foci. In this model, mean JZ thickness, JZ/MYO > 40 and the presence of HSI foci reached statistical significance. Preference was given to variables with the most statistical significance in univariate analysis, and the number of included variables in the model was kept to a minimum. To further correct the model for overfitting, a shrinkage factor of .747 was applied. Since LOESS already showed a good model fit for the continuous variables of interest, no modifications were necessary. The formula for the final prediction model therefore is as follows:

$$Y = \frac{1}{1 + e^{-(-3.246 + (\text{age} \cdot .032) + (\text{BMI} \cdot .026) + (\text{history of curettage}(\text{yes} = 1 \text{ no} = 0) \cdot .633)) + (\text{dysmenorrhoea}(\text{yes} = 1 \text{ no} = 0) \cdot .073) + (\text{AUB}(\text{yes} = 1 \text{ no} = 0) \cdot .028) + (\text{mean JZ} \cdot .138) + (\text{JZ Diff} \geq 5 \text{ mm}(\text{yes} = 1 \text{ no} = 0) \cdot .320) - (\text{JZ/MYO} > .04(\text{yes} = 1 \text{ no} = 0) \cdot 1.226) + (\text{HSI Foci}(\text{yes} = 1 \text{ no} = 0) \cdot 1.148)}}$$

Discrimination performance evaluation of this prediction model showed an AUC of .776. A sub-analysis was conducted to assess whether the clinical query presented to the pathologist affected model diagnostic performance. The pathologist was directly asked to assess for the presence of adenomyosis in 142/296 patients. Model diagnostic performance did not improve significantly when adenomyosis was specifically evaluated for (data not shown).

Calibration performance evaluation showed an observed to expected ratio of 1.2, and the Hosmer and Lemeshow test that did not reach statistical significance ($p = .688$).

4. Discussion

We assessed clinical and MRI parameters for their potential to predict histopathological adenomyosis diagnosis prior to hysterectomy. The resultant multivariate prediction model discriminates well between patients with and without adenomyosis (AUC 0.776). Five clinical characteristics: age at MRI, BMI, history of curettage, dysmenorrhoea, and AUB, and four primary MRI parameters: mean JZ thickness, JZ Diff ≥ 5 mm, JZ/MYO > .40, and the presence of HSI foci are included.

To the best of our knowledge, no comparable models for histopathological adenomyosis diagnosis based on MRI exist. Previous studies have investigated prediction of adenomyosis diagnosis based on ultrasound, with comparable accuracy [9,11,25]. However, it is known that ultrasound diagnosis is highly operator dependent, with varying inter- and intra-observer variability [8,26,27]. An MRI prediction model such as developed in our study thus has clinical value especially in cases where adenomyosis co-exists with other pathology (as was the case in the majority of our included patients), or is mild, or atypical.

The parameters ultimately included in this model are unsurprising when considering reported adenomyosis clinical presentation and aetiology. Dysmenorrhoea and AUB are the most frequently reported symptoms of adenomyosis [4,28] and were thus logical (and statistically significant) additions to the model. Age at MRI was further included in the model due to the known physiological increase in JZ thickness with age [29–31]. BMI was also manually entered into the model as, despite univariate analysis showing no significant association, increased body weight and obesity have been reported as strong risk factors for adenomyosis [32].

History of curettage (after miscarriage) established itself to be an important predictor and was thus included in our model. It is debatable as to if curettage is a cause or a consequence of adenomyosis, as adenomyosis is often associated with risk of miscarriage [5]. Conversely, curettage as a risk factor for the development of adenomyosis could potentially be explained by iatrogenic trauma leading to the mechanical transport of endometrial cells into the myometrium [33,34].

None of the primary MRI parameters alone were sufficient to diagnose adenomyosis conclusively, which is in line with the literature [35]. The presence of HSI foci emerged as the strongest predictor of the assessed MRI parameters ($p < .001$). Bazot et al. indeed described these foci as the only direct diagnostic criterion and almost pathognomonic for adenomyosis on MRI, although they are only detected in about half the cases [35]. We also find, in agreement with recent insights into the (lack of) diagnostic potential of JZ markers [36–38], that JZ thickness alone is not specific enough to diagnose adenomyosis on MRI. Notably in our cohort for instance, the mean maximum JZ in the non-adenomyosis cohort was already over the often reported cut-off value of 12 mm (see Table 2, [39]) for adenomyosis, illustrating how attaching (too) much weight to this as a diagnostic marker is not reliable. This is further reflected in the low accuracy of MRI diagnosis overall for adenomyosis of 59.4% (see Table 3) in our cohort, for which JZ thickness > 12 mm was a main criterion. However, our results do suggest that the likelihood of adenomyosis increases with a larger JZ, especially if it is also irregular or proportionally takes up a large part of the total myometrium (as reflected in the markers JZ Diff and JZ/MYO ratio, see Tables 2 and 4). For this reason, it still included our model as a diagnostic marker, but without attaching a cut-off value for its general (maximum) thickness.

This study has several strengths and limitations that merit consideration. One strength of our study is that two researchers independently reviewed all pelvic MRIs blinded to the histopathology outcome. Furthermore, the proposed model was built on data of 296 patients and data driven variable selection was avoided, along with corrections for potential overfitting. Additionally, the combination of both clinical and MRI parameters makes this model easily implementable into daily clinical practise.

The present study used broad inclusion criteria, which could be interpreted as both a strength and limitation. On the one hand, inclusion of patients with comorbidities like uterine fibroids might have prevented an overestimation of diagnostic performance of the individual potential predictors. Alternatively, severe distortion of the uterus due to fibroids or endometriosis can limit the ability for complete objective assessment of all MRI parameters.

One limitation of the current study is that it was not possible to correct for the influence of the menstrual cycle on MRI parameters. Although it is known that JZ thickness changes during the menstrual cycle [29], cycle phase at time of MRI was not reported for most of our patients. Furthermore, the choice for histopathology after hysterectomy as a reference standard introduces an element of selection bias. Potentially, our group consisted of women with more severe adenomyosis and thus may have affected the general phenotype. The present study did not conduct a central review of pathology however, and (histological) adenomyosis severity was generally not reported in pathology reports. Therefore, this remains hypothetical. Similarly, future validation is needed to confirm the applicability of this model in women without indication for hysterectomy.

In clinical practice, our model could be used to calculate the risk of adenomyosis in individual patients. For example, in a 31-year-old woman with a BMI of 19 kg/m², without history of curettage, with complaints of both dysmenorrhoea and AUB, and an MRI with mean JZ thickness of 8.3 millimetres, a JZ Diff < 5 mm, a JZ/MYO > 40 , but HSI foci (Fig. 2A), the probability of adenomyosis is 14.9%. In a 35-year-old woman with a BMI of 24 kg/m², without history of curettage, with complaints of both dysmenorrhoea and AUB, and an MRI with a mean JZ thickness of 24.6 millimetres, a JZ Diff ≥ 5 mm, a JZ/MYO > 40 and HSI foci (Fig. 2B), this probability increases to 90.3%.

In conclusion, we present an MRI-based clinical prediction model for histopathological adenomyosis diagnosis. In future, this tool can be useful for both patients and clinicians, with a potential to reduce morbidity and to contribute to shared decision-making. Since patient management depends on several factors, such as age, symptoms, and comorbidity, the clinical use of the predicted risks from the proposed model should still be decided on an individual basis. Thus, before steps are made for use in clinical practise, external validation of the model is needed.

Funding

None.

Contribution

CR, HvV and BC conceived and designed the study. MvdW and CR collected and analysed the data, and drafted the manuscript. JN gave access to crucial data and offered expertise in data collection and analysis of MRIs specifically. JN, AH and MM made critical contributions to the presentation, revision and interpretation of the final results, and approved the final version to be published. All authors concurred with the final version of this manuscript.

Connie Rees: conceptualisation, data curation, formal analysis, investigation, methodology, project administration, visualisation, writing (original draft).

Marloes van de Wiel: methodology, data curation, formal analysis, investigation, writing (original draft).

Joost Nederend: writing (review and editing), resources, software, supervision.

Aleida Huppelschoten: writing (review and editing), supervision, validation.

Massimo Mischi: writing (review and editing), supervision.

Hubertus van Vliet: conceptualisation, methodology, project administration, supervision, writing (review and editing).

Benedictus Schoot: conceptualisation, methodology, project administration, supervision, writing (review and editing).

Disclosure of interest

Benedictus Schoot reports a relationship with GE Healthcare that includes: funding grants. Hubertus van Vliet reports a relationship with Medtronic Inc that includes: speaking and lecture fees.

The other authors declare that they have no competing interest.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.jeud.2023.100028>.

References

- [1] Tellum T, Nygaard S, Lieng M. Noninvasive diagnosis of adenomyosis: a structured review and meta-analysis of diagnostic accuracy in imaging. *J Minim Invasive Gynecol* 2019;27:408–18 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31712162>].
- [2] Dueholm M, Hjorth IMD. Structured imaging technique in the gynecologic office for the diagnosis of abnormal uterine bleeding. *Best Pract Res Clin Obstet Gynaecol*

- [Internet] 2017;40:23–43 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/27818130>].
- [3] Rees CO, Nederend J, Mischi M, van Vliet HAAM, Schoot BC. Objective measures of adenomyosis on MRI and their diagnostic accuracy — a systematic review & meta-analysis. *Acta Obstet Gynecol Scand* 2021;100:1377–91.
- [4] Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. *Hum Reprod Update* 2020;26:392–411.
- [5] Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. *Hum Reprod Update* 2019;25:593–633.
- [6] Protopapas A, Grimbizis G, Athanasiou S, Loutradis D. Adenomyosis: Disease, uterine aging process leading to symptoms, or both? *Facts Views Vis ObGyn* [Internet] 2020;12(2):91 [cited 2022 Jun 28, available from: <https://pmc/articles/PMC7431194/>].
- [7] Van den Bosch T, Van Schoubroeck D. Ultrasound diagnosis of endometriosis and adenomyosis: State of the art. *Best Pract Res Clin Obstet Gynaecol* [Internet] 2018;51:16–24 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29506961>].
- [8] Van den Bosch T, de Bruijn AM, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Sonographic classification and reporting system for diagnosing adenomyosis. *Ultrasound Obstet Gynecol* 2019;53:151.
- [9] Tellum T, Nygaard S, Skovholt EK, Qvigstad E, Lieng M. Development of a clinical prediction model for diagnosing adenomyosis. *Fertil Steril* 2018;110(5):957–64 [e3].
- [10] Bazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine JM, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. *Hum Reprod* 2001;16:2427–33.
- [11] Andres MP, Borrelli GM, Ribeiro J, Baracat EC, Abrão MS, Kho RM. Transvaginal ultrasound for the diagnosis of adenomyosis: systematic review and meta-analysis. *J Minim Invasive Gynecol* 2018;25(2):257–64.
- [12] Lazzeri L, Di Giovanni A, Exacoustos C, Tosti C, Pinzauti S, Malzoni M, et al. Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis. *Reproductive sciences* 2014 Aug;21:1027–33.
- [13] Valentini AL, Speca S, Gui B, Soglia BG, Miccò M, Bonomo L. Adenomyosis: from the sign to the diagnosis. Imaging, diagnostic pitfalls and differential diagnosis: a pictorial review. *Radiol Med* 2011;116:1314.
- [14] Gonzales M, de Matos LA, da Costa Gonçalves MO, Blasbalg R, Dias Junior JA, Podgaec S, et al. Patients with adenomyosis are more likely to have deep endometriosis. *Gynecological Surgery* 2012;9:259–64.
- [15] Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al. Clinical diagnosis of endometriosis: a call to action. *Am J Obstet Gynecol* 2019;220(4):354e1–354e12.
- [16] Staal AHJ, Van Der Zanden M, Nap AW. Diagnostic delay of endometriosis in the Netherlands. *Gynecol Obstet Invest* 2016;81(4):321–4.
- [17] Gambadauro P, Carli V, Hadlaczky G. Depressive symptoms among women with endometriosis: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2019;220:230–41 [Mosby Inc.].
- [18] Agostinho L, Cruz R, Osório F, Alves J, Setúbal A, Guerra A. MRI for adenomyosis: a pictorial review. *Insights Imaging* [Internet] 2017;8(6):549–56 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28980163>].
- [19] Munro MG. Classification systems for adenomyosis. *J Minim Invasive Gynecol* 2019;27:296–308 [Internet] [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31785418>].
- [20] Kishi Y, Suginami H, Kuramori R, Yabuta M, Suginami R, Taniguchi F. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification. *Am J Obstet Gynecol* [Internet] 2012;207(2):114 [e1–7. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22840719>].
- [21] Kobayashi H, Matsubara S. A classification proposal for adenomyosis based on magnetic resonance imaging. *Gynecol Obstet Invest* 2020;85(2):118–26.
- [22] Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies*. *Bull World Health Organ* [Internet] 2007;85(11):867–72 [cited 2022 Apr 11. Available from: <http://www.strobe-statement.org>].
- [23] Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine* 2015;162:W1–W73.
- [24] Grant SW, Collins GS, Nashef SAM. Statistical primer: developing and validating a risk prediction model†. *Cardiothorac Surg* [Internet] 2018;54:203–11 [Available from: <https://academic.oup.com/ejcts/article/54/2/203/4993384>].
- [25] Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. *Acta Obstet Gynecol Scand* 2010;89:1374–84.
- [26] Rasmussen CK, Hansen ES, Dueholm M. Inter-rater agreement in the diagnosis of adenomyosis by 2- and 3-dimensional transvaginal ultrasonography. *J Ultrasound Med* [Internet] 2019;38(3):657–66 [cited 2022 Aug 1. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/jum.14735>].
- [27] Habiba M, Gordts S, Bazot M, Brosens I, Benagiano G. Exploring the challenges for a new classification of adenomyosis. *Reprod Biomed Online* 2020;40(4):569–81.
- [28] Aleksandrovych V, Basta P, Gil K. Current facts constituting an understanding of the nature of adenomyosis. *Adv Clin Exp Med* 2019:28.
- [29] Meylaerts LJ, Wijnen L, Grieten M, Palmers Y, Ombelet W, Vandersteen M. Junctional zone thickness in young nulliparous women according to menstrual cycle and hormonal contraception use. *Reprod Biomed Online* 2017;34(2):212–20.
- [30] Maubon A, Faury A, Kapella M, Pouquet M, Piver P. Uterine junctional zone at magnetic resonance imaging: a predictor of in vitro fertilization implantation failure. *J Obstet Gynaecol Res* 2010;36(3):611–8.
- [31] Hauth EAM, Jaeger HJ, Libera H, Lange S, Forsting M. MR imaging of the uterus and cervix in healthy women: determination of normal values. *Eur Radiol* [Internet] 2007;17(3):734–42 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/16703306>].
- [32] Templeman C, Marshall SF, Ursin G, Horn-Ross PL, Clarke CA, Allen M, et al. Adenomyosis and endometriosis in the California Teachers Study. *Fertil Steril* 2008;90(2):415–24.
- [33] Guo SW. The pathogenesis of adenomyosis vis-à-vis endometriosis. *J Clin Med* [Internet] 2020;9(2):485 [cited 2020 Aug 3. Available from: <https://www.mdpi.com/2077-0383/9/2/485>].
- [34] Leyendecker G, Bilgicyildirim A, Inacker M, Stalf T, Huppert P, Mall G, et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. *Arch Gynecol Obstet* 2015;291:917–32.
- [35] Bazot M, Darai E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. *Fertil Steril* 2018;109(3):389–97.
- [36] Harmsen MJ, Van den Bosch T, Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Consensus on revised definitions of morphological uterus sonographic assessment (MUSA) features of adenomyosis: results of a modified Delphi procedure. *Ultrasound Obstet Gynecol* 2021;60(1):118–31.
- [37] Harmsen MJ, Trommelen LM, de Leeuw RA, Tellum T, Juffermans LJM, Griffioen AW, et al. Multidisciplinary view on uterine junctional zone in uteri affected by adenomyosis: explaining discrepancies between MRI and transvaginal ultrasound images on a microscopic level. *Ultrasound Obstet Gynecol* 2022;0–3.
- [38] Tellum T, Munro MG. Classifications of adenomyosis and correlation of phenotypes in imaging and histopathology to clinical outcomes: a review. *Curr Obstet Gynecol Rep* [Internet] 2022;11(1):1–11, doi:<http://dx.doi.org/10.1007/s13669-021-00320-55>.
- [39] Tellum T, Matic GV, Dormagen JB, Nygaard S, Viktil E, Qvigstad E, et al. Diagnosing adenomyosis with MRI: a prospective study revisiting the junctional zone thickness cutoff of 12 mm as a diagnostic marker. *Eur Radiol* [Internet] 2019;29(12):6971–81 [Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31264010>].



Connie O. Rees

Connie Rees is a Gynaecology & Obstetrics resident completing her training under the umbrella of Ghent University Hospital in Belgium and is pursuing her PhD at the Eindhoven University of Technology in the Netherlands. Her PhD research focuses on the (imaging) diagnosis of adenomyosis and the influence of adenomyosis on fertility and obstetric outcomes.